Peter Lebowitz, outgoing head of J&J oncology (via website)
October 31, 2023 12:38 PM EDTUpdated 12:57 PM
Bioregnum
R&D

Long­time can­cer R&D chief Pe­ter Lebowitz is tak­ing his fi­nal bows at J&J on­col­o­gy. Now what?

John Carroll

Editor & Founder

As the head of John­son & John­son’s on­col­o­gy R&D, Pe­ter Lebowitz’s port­fo­lio ran the sci­en­tif­ic gamut, from dis­cov­ery through de­vel­op­ment and on to the big …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times